

13

trifluoroacetyl, p-toluy, t-butoxycarbonyl or 2,2,2-trichloro-t-butoxycarbonyl, and  
 x, y and z, same or different, are 2 to 12, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier therefor.

13. A pharmaceutical composition as recited in claim 12, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, same or different, are hydrogen, C<sub>5-6</sub> cycloalkyl, C<sub>1-4</sub> straight or branched chain alkyl, benzyl or acetyl.

14. A pharmaceutical composition as recited in claim 13, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, same or different, are hydrogen, methyl, ethyl, benzyl or acetyl; and

14

x, y and z, same or different, are 2 to 4.

15. A pharmaceutical composition as recited in claim 14, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, same or different, are hydrogen, methyl or acetyl.

16. A pharmaceutical composition as recited in claim 12, wherein the Formula I compound is:

$\text{CH}_3\text{—NH}^+\text{—}(\text{CH}_2)_4\text{—N}(\text{—N}_2\text{O}_2^-)(\text{—CH}_3),$

$\text{H}_3\text{N}^+\text{—}(\text{CH}_2)_3\text{—NH—}(\text{CH}_2)_4\text{—N—}(\text{—N}_2\text{O}_2^-)$

$][\text{—}(\text{CH}_2)_3\text{NH}_2]$  or a tautomer thereof,

$\text{H}_3\text{N}^+\text{—}(\text{CH}_2)_3\text{—N}(\text{—N}_2\text{O}_2^-)[\text{—}(\text{CH}_2)_2\text{—CH}_3],$

$\text{H}_3\text{N}^+\text{—}(\text{CH}_2)_3\text{—N}(\text{—N}_2\text{O}_2^-)[\text{—}(\text{CH}_2)_4\text{NH}_2]$  or a tautomer thereof; or

a pharmaceutically acceptable salt thereof.

\* \* \* \* \*

20

25

30

35

40

45

50

55

60

65